Is BioNexus Gene Lab Corp. overvalued or undervalued?

As of 9 December 2022, the valuation grade for BioNexus Gene Lab Corp. moved from very expensive to risky. The company is currently assessed as overvalued, given its significant financial challenges and negative performance indicators. The P/E ratio is not applicable due to losses, while the Price to Book Value stands at 0.72, indicating a potential undervaluation relative to its book value. However, the EV to Sales ratio is low at 0.22, reflecting weak sales performance.
In comparison to peers, BioNexus Gene Lab Corp. has a notably negative EV to EBITDA ratio of -0.95, while SilverSun Technologies, Inc. is in an attractive position with an EV to EBITDA of -60.0379. Other risky peers like Team, Inc. and CervoMed, Inc. also reflect challenging valuations with EV to EBITDA ratios of 9.7131 and -1.2513, respectively. Additionally, the company's recent stock performance has been poor, with a 1-year return of -41.01%, contrasting sharply with the S&P 500's 10.26% return, further supporting the conclusion of overvaluation.